

Amendments to the Specification

Page 21, after first paragraph, please insert the following:

BRIEF DESCRIPTION OF THE DRAWINGS

In the accompanying drawings,

Fig. 1 is a graph representing the results obtained by treating mice having induced autoimmune encephalomyelitis with an alanyl aminopeptidase inhibitor of the present invention, optionally in combination with a dipeptidyl peptidase IV inhibitor (see Example 2);

Fig. 2 is a graph representing the results obtained by treating mice having dextrane sulfate-induced colitis with an alanyl aminopeptidase inhibitor of the present invention, optionally in combination with a dipeptidyl peptidase IV inhibitor (see Example 3);

Fig. 3A is a graph representing the results obtained by treating mice having ovalbumine-induced asthma bronchiale with an alanyl aminopeptidase inhibitor of the present invention, optionally in combination with a dipeptidyl peptidase IV inhibitor, expressed in terms of the reduction of the average expiratory flux (EF 50) as a measure of the pulmonic function (see Example 4); and

Fig. 3B is a graph representing the results obtained by treating mice having ovalbumine-induced asthma bronchiale with an alanyl aminopeptidase inhibitor of the present invention, optionally in combination with a dipeptidyl peptidase IV inhibitor, expressed in terms of eosinophils as a characteristic feature of the asthma bronchiale pulmonic inflammation (see Example 4).